Phase Ib study of avadomide (CC‐122) in combination with rituximab in patients with relapsed/refractory diffuse large B‐cell lymphoma and follicular lymphoma

The multicenter, phase Ib CC‐122‐DLBCL‐001 dose‐expansion study (NCT02031419) explored the cereblon E3 ligase modulator (CELMoD) agent avadomide (CC‐122) plus rituximab in patients with relapsed/refractory (R/R) diffuse large B‐cell lymphoma (DLBCL) or follicular lymphoma (FL). Patients received ava...

Descripción completa

Detalles Bibliográficos
Autores principales: Nastoupil, Loretta J., Kuruvilla, John, Chavez, Julio C., Bijou, Fontanet, Witzig, Thomas E., Santoro, Armando, Flinn, Ian W., Boccomini, Carola, Kenkre, Vaishalee P., Corradini, Paolo, Isufi, Iris, Andorsky, David J., Klein, Leonard M., Greenwald, Daniel R., Sangha, Randeep, Shen, Frank, Hagner, Patrick, Li, Yan, Dobmeyer, Juergen, Gong, Nian, Uttamsingh, Shailaja, Pourdehnad, Michael, Ribrag, Vincent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Haematologic Malignancy ‐ Lymphoid
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175947/
https://www.ncbi.nlm.nih.gov/pubmed/35846031
http://dx.doi.org/10.1002/jha2.394

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175947/
https://www.ncbi.nlm.nih.gov/pubmed/35846031
http://dx.doi.org/10.1002/jha2.394

Ejemplares similares